Evidence map›Paper›PMID 29596588›Full record

ArticleJAMA ophthalmology2018

Incidence of and Risk Factors Associated With Age-Related Macular Degeneration: Four-Year Follow-up From the ALIENOR Study.

Valentine Saunier, Bénédicte M J Merle, Marie-Noëlle Delyfer, Audrey Cougnard-Grégoire, Marie-Bénédicte Rougier, Philippe Amouyel, Jean-Charles Lambert, Jean-François Dartigues, Jean-François Korobelnik, Cécile Delcourt

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in JAMA ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01555827 (Retinal Neurodegenerative Signs in Alzheimer's Diseases), which is not on this map. Cited by 51 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 3 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01555827 nacompletednot on this map

Retinal Neurodegenerative Signs in Alzheimer's Diseases

TypeinterventionalSponsorUniversity Hospital, BordeauxRan2012 to 2014Enrolled200ConditionsAlzheimer's DiseaseArmsOphthalmological examination & Questionnaire
3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 3 syntheses or guidelines pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Immunogenetic and Environmental Factors in Age-Related Macular Disease.International journal of molecular sciences · 2024
    Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Valentine SaunierUniversité de Bordeaux, INSERM, Bordeaux Population Health Research Center, Team Lifelong Exposures, Health, and Aging (LEHA), UMR 1219, Bordeaux, France.
Bénédicte M J MerleUniversité de Bordeaux, INSERM, Bordeaux Population Health Research Center, Team Lifelong Exposures, Health, and Aging (LEHA), UMR 1219, Bordeaux, France.
Marie-Noëlle DelyferUniversité de Bordeaux, INSERM, Bordeaux Population Health Research Center, Team Lifelong Exposures, Health, and Aging (LEHA), UMR 1219, Bordeaux, France.
Audrey Cougnard-GrégoireUniversité de Bordeaux, INSERM, Bordeaux Population Health Research Center, Team Lifelong Exposures, Health, and Aging (LEHA), UMR 1219, Bordeaux, France.
Marie-Bénédicte RougierUniversité de Bordeaux, INSERM, Bordeaux Population Health Research Center, Team Lifelong Exposures, Health, and Aging (LEHA), UMR 1219, Bordeaux, France.
Philippe AmouyelUniversité de Lille, INSERM U1167, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, DISTALZ Laboratoire d'Excellence, Lille, France.
Jean-Charles LambertUniversité de Lille, INSERM U1167, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, DISTALZ Laboratoire d'Excellence, Lille, France.
Jean-François DartiguesUniversité de Bordeaux, INSERM, Bordeaux Population Health Research Center, Team Lifelong Exposures, Health, and Aging (LEHA), UMR 1219, Bordeaux, France.
Jean-François KorobelnikUniversité de Bordeaux, INSERM, Bordeaux Population Health Research Center, Team Lifelong Exposures, Health, and Aging (LEHA), UMR 1219, Bordeaux, France.
Cécile DelcourtUniversité de Bordeaux, INSERM, Bordeaux Population Health Research Center, Team Lifelong Exposures, Health, and Aging (LEHA), UMR 1219, Bordeaux, France.
Inserm · FRUniversité de Bordeaux · FRCentre Hospitalier Universitaire de Bordeaux · FRUniversité de Lille · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: While the prevalence of age-related macular degeneration (AMD) differs according to continents and races/ethnicities, its incidence in the European continent has been scarcely documented. Objective: To describe the incidence and associated risk factors of AMD in elderly French individuals. Design, Setting, and Participants: This population-based cohort study of 963 residents of Bordeaux, France, who were 73 years or older at baseline and participated in the Antioxydants, Lipides Essentiels, Nutrition et Maladies Oculaires (ALIENOR) Study between October 2, 2006, and December 21, 2012. Of 829 participants at risk for incident AMD, 659 (79.5%) were observed for a mean (SD) duration of 3.8 (1.1) years. Data were analyzed from August 2016 to March 2017. Main Outcomes and Measures: Age-related macular degeneration was graded from retinal photographs and spectral-domain optical coherence tomography into 5 exclusive stages: no AMD, early AMD1, early AMD2, late atrophic AMD, and late neovascular AMD. Results: Of the 659 eligible participants, 413 (62.7%) were women, and the mean (SD; range) age was 79.7 (4.4; 73-94) years. A total of 120 incident cases of early AMD and 45 incident cases of advanced AMD were recorded. Incidence rates of early and advanced AMD were 79.9 (95% CI, 66.8-95.5) per 1000 person-years and 18.6 (95% CI, 13.9-24.9) per 1000 person-years, respectively, corresponding to 5-year risks of 32.9% and 8.9%. Incidence of advanced AMD per 1000 eye-years was 1.5 in eyes without any AMD at baseline, 42.4 in those with early AMD1, and 85.1 in those with early AMD2. In multivariate analysis without correction for multiple testing, progression from early to advanced AMD was associated with AMD grade in the fellow eye (hazard ratio [HR] according to grade, 13.0 [95% CI, 2.8-61.2] to 22.5 [95% CI, 2.6-195.9]), having smoked at least 20 pack-years (calculated as number of smoking years × mean number of cigarettes per day / 20; HR, 3.0; 95% CI, 1.4-6.5), and complement factor H (CFH) Y402H genotype (CC genotype: HR, 2.3; 95% CI, 1.0-5.3; TC genotype: HR, 1.5; 95% CI, 0.6-3.7). Incidence of early AMD was associated with early AMD in the fellow eye (early AMD1: HR, 2.6; 95% CI, 1.6-4.2; early AMD2: HR, 5.6; 95% CI, 3.3-9.4) and high plasma high-density lipoprotein cholesterol levels (HR, 1.2; 95% CI, 1.0-1.4). Conclusions and Relevance: In this cohort, AMD incidence rates were similar to those observed in other European populations. This study suggests a high risk for incident early AMD in individuals with high plasma high-density lipoprotein cholesterol levels while confirming the high risk for progression from early to advanced AMD in heavy smokers and carriers of CFH Y402H at-risk genotypes.

Indexed as

AgedAged, 80 and overCohort StudiesComplement Factor HDisease ProgressionFemaleFollow-Up StudiesFranceGenotypeHumansIncidenceMacular DegenerationMalePhotographyPolymorphism, GeneticRisk FactorsCFH protein, humanComplement Factor H

Identifiers

PMID29596588
PMCPMC5876848
OpenAlexW2794808880

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.